Delayed preconditioning via angiotensin-converting enzyme inhibition: Pros and cons from an experimental study

Clinical and Experimental Pharmacology and Physiology

Volumn 33, Issue 9, 2006, Pages 787-792

  Marktanner, Ralph ^a   Nacke, Peter ^a   Feindt, Peter ^a   Hohlfeld, Thomas ^b   Schipke, Jochen D ^a   Gams, Emmeran ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Cardiac function; Coronary artery bypass surgery; Hypoxia reperfusion; Interventional cardiology; Pharmacological preconditioning

Indexed keywords

BRADYKININ B2 RECEPTOR; BUFFER; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; ENZYME INHIBITION; EXPERIMENTAL STUDY; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE RELAXATION; HEART PROTECTION; HEART VENTRICLE EXTRASYSTOLE; HYPOXIA; ISOLATED HEART; MALE; NONHUMAN; RABBIT; REPERFUSION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANOXIA; ARRHYTHMIA; BIOLOGICAL MARKERS; CAPTOPRIL; CORONARY VESSELS; DRUG EVALUATION, PRECLINICAL; ISCHEMIC PRECONDITIONING; MALE; MYOCARDIUM; RABBITS; REGIONAL BLOOD FLOW; REPERFUSION INJURY; VENTRICULAR FUNCTION;

EID: 33747059845     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2006.04439.x     Document Type: Article

References (31)

1. Marktanner R, Nacke P, Feindt P, Hohlfeld T, Gams E. Norepinephrine- induced delayed cardioprotection against stunning is at the expense of a higher postischemic arrhythmia rate. Cardiovasc. Surg. 2003; 11: 475-82.
2. Post H, Heusch G. Ischemic preconditioning. Experimental facts and clinical perspective. Minerva Cardioangiol. 2002; 50: 569-605.
3. Vegh A, Szekeres L, Parratt JR. Local intracoronary infusions of bradykinin profoundly reduce the severity of ischaemia-induced arrhythmias in anaesthetized dogs. Br. J. Pharmacol. 1991; 104: 294-5.
4. Sun W, Wainwright CL. The potential antiarrhythmic effects of exogenous and endogenous bradykinin in the ischaemic rat heart in vivo. Coron. Artery Dis. 1994; 5: 541-50.
5. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36.
6. Ovize M, Aupetit JF, Rioufol G et al. Preconditioning reduces infarct size but accelerates time to ventricular fibrillation in ischemic pig heart. Am. J. Physiol. 1995; 269: H72-9.
7. Leesar MA, Stoddard MF, Manchikalapudi S, Bolli R. Bradykinin-induced preconditioning in patients undergoing coronary angioplasty. J. Am. Coll. Cardiol. 1999; 34: 639-50.
8. Lambiase PD, Edwards RJ, Cusack MR, Bucknall CA, Redwood SR, Marber MS. Exercise-induced ischemia initiates the second window of protection in humans independent of collateral recruitment. J. Am. Coll. Cardiol. 2003; 41: 1174-82.
9. Strauer BE, Heidland UE, Heintzen MP, Schwartzkopff B. Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty by intracoronary application of dipyridamole: Impact on hemodynamic function and left ventricular performance. J. Am. Coll. Cardiol. 1996; 28: 1119-26.
10. Wang X, Wei M, Kuukasjarvi P et al. Novel pharmacological preconditioning with diazoxide attenuates myocardial stunning in coronary artery bypass grafting. Eur. J. Cardiothorac. Surg. 2003; 24: 967-73.
11. Ruiz Ros JA, Ortega VV, Martinez JA et al. Stunned myocardium and cellular damage in patients undergoing valvular cardiac surgery and pretreated with captopril. J. Cardiovasc. Surg. 1999; 40: 203-10.
12. Huang LJ, Chen SX, Lou WJ. [Delayed cardioprotection of captopril in patients undergoing open heart surgery]. Hunan Yi Ke Da Xue Xue Bao 2001; 26: 73-6 (in Chinese).
13. Peart JN, Gross GJ. Exogenous activation of delta- and kappa-opioid receptors affords cardioprotection in isolated murine heart. Basic Res. Cardiol. 2004; 99: 29-37.
14. Schriefer JA, Broudy EP, Hassen AH. Inhibitors of bradykininin-activating enzymes decrease myocardial ischemia/reperfusion injury following 3 and 7 days of reperfusion. J. Pharmacol. Exp. Ther. 2001; 298: 970-5.
15. Kositprapa C, Ockaili RA, Kukreja RC. Bradykinin B2 receptor is involved in the late phase of preconditioning in rabbit heart. J. Mol. Cell. Cardiol. 2001; 33: 1355-62.
16. Leesar MA, Stoddard MF, Dawn B, Jasti VG, Masden R, Bolli R. Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty. Circulation 2001; 103: 2935-41.
17. Ebrahim Z, Baxter GF, Yellon DM. Omapatrilat limits infarct size and lowers the threshold for induction of myocardial preconditioning through a bradykinin receptor-mediated mechanism. Cardiovasc. Drugs Ther. 2004; 18: 127-34.
18. Morris SD, Yellon DM. Angiotensin-converting enzyme inhibitors potentiate preconditioning through bradykinin B2 receptor activation in human heart. J. Am. Coll. Cardiol. 1997; 29: 1599-606.
19. Dogan R, Sarigul A, Isbir S et al. Beneficial effect of captopril against ischaemia-reperfusion injury in isolated guinea pig hearts. Scand. J. Clin. Lab. Invest. 1998; 58: 119-26.
20. Jaberansari MT, Baxter GF, Muller CA et al. Angiotensin-converting enzyme inhibition enhances a subthreshold stimulus to elicit delayed preconditioning in pig myocardium. J. Am. Coll. Cardiol. 2001; 37: 1996-2001.
21. Heusch G, Schulz R. Perfusion-contraction match and mismatch. Basic Res. Cardiol. 2001; 96: 1-10.
22. Burkhoff D. Myocardial energetics and the postischemic heart. Ann. Thorac. Surg. 1990; 49: 525-7.
23. Schipke JD. Cardiac efficiency. Basic Res. Cardiol. 1994; 89: 207-40.
24. Sunderdiek U, Schmitz-Spanke S, Korbmacher B, Gams E, Schipke JD. Left ventricular dysfunction and disturbed O(2)-utilization in stunned myocardium: Influence of ischemic preconditioning. Eur. J. Cardiothorac. Surg. 2001; 20: 770-6.
25. Rooke GA, Feigl EO. Work as a correlate of canine left ventricular oxygen consumption, and the problem of catecholamine oxygen wasting. Circ. Res. 1982; 50: 273-86.
26. Hall JM. Bradykinin receptors. Gen. Pharmacol. 1997; 28: 1-6.
27. Goto M, Liu Y, Yang XM, Ardell JL, Cohen MV, Downey JM. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ. Res. 1995; 77: 611-21.
28. Miki T, Miura T, Ura N et al. Captopril potentiates the myocardial infarct size-limiting effect of ischemic preconditioning through bradykinin B2 receptor activation. J. Am. Coll. Cardiol. 1996; 28: 1616-22.
29. Brunner F, Kukovetz WR. Postischemic antiarrhythmic effects of angiotensin-converting enzyme inhibitors. Role of suppression of endogenous endothelin secretion. Circulation 1996; 94: 1752-61.
30. Vaage J, Valen G. Preconditioning and cardiac surgery. Ann. Thorac. Surg. 2003; 75: S709-14.
31. Ghosh S, Galinanes M. Protection of the human heart with ischemic preconditioning during cardiac surgery: Role of cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 2003; 126: 133-42.